S&P 500 Dispels “Sell in May” Myth With Strong Summer Gains

As of the end of August, the index's year-to-date gains exceed 20%.

Record-setting earnings, official FDA approval of the Pfizer vaccine and anticipation that booster shots will begin in September helped drive equity markets steadily higher in August. The S&P 500 index, a common measure for U.S. large-cap performance, reached 12 highs during the month on its way to gains of roughly 3%.

Since Memorial Day, the S&P 500 has gained more than 7%, belying the idea that equity markets take the summer off.

“Summer strength continued in August, dispelling the myth that investors ‘sell in May and go away,’” said Raymond James Chief Investment Officer Larry Adam. “Investors looked past the resurgence in COVID-19 cases, which has had only limited impacts to economic momentum so far.”

U.S. Federal Reserve officials and most economists believe recent inflation will be transitory, though production bottlenecks and other supply issues are likely to continue for a while, according to Chief Economist Scott Brown.

The Federal Reserve is expected to start reducing (“tapering”) its monthly asset purchases – currently $120 billion – later this year. However, “any increase in short-term interest rates is still a long way off,” Brown said.

 

12/31/20 Close

8/31/21 Close

Change
Year to Date

% Gain/Loss
Year to Date

DJIA

30,606.48

35,360.73

+4,754.25

+15.53%

NASDAQ

12,888.28

15,259.24

+2,370.96

+18.40%

S&P 500

3,756.07

4,522.68

+766.61

+20.41%

MSCI EAFE

2,147.53

2,358.28

+210.75

+9.81%

Russell 2000

1,974.86

2,273.77

+298.91

+15.14%

Bloomberg Barclays
U.S. Aggregate Bond Index

2,392.02

2,378.43

-13.59

-0.57%

Performance reflects price returns as of market close on August 31, 2021. MSCI EAFE and the Bloomberg Aggregate Bond figures reflect August 30, 2021, closing values.